Role of miR-124a in HTLV-I oncogenesis
Role of miR-124a in HTLV-I oncogenesis
批准号:
8287054
负责人:
CHRISTOPHE P NICOT
金额:
$16.31万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-07-01 至 2013-06-30
关键词:
AcuteAdultAffectApoptoticBCL2 geneBiologicalBiological AssayCD4 Positive T LymphocytesCell CycleCell ProliferationCell SurvivalCellsClonal ExpansionDataDiseaseDisease ProgressionDown-RegulationEpigenetic ProcessGene TargetingGenomeGrowthHumanHuman T-lymphotropic virus 1HypermethylationIncidenceInfectionLymphomaLymphomagenesisLymphoproliferative DisordersMalignant NeoplasmsMediatingMicroRNAsMolecularMutationOncogenicOnset of illnessOutcomePathogenesisPathway interactionsPatientsPhaseProcessRadiation therapyRegimenRelapseReportingRoleSTAT3 geneSiteT-Cell LeukemiaViralViral GenomeVirusVirus DiseasesVirus Replicationbasecell transformationcellular targetingchemotherapyhuman diseasein vitro Assayleukemiametaplastic cell transformationnew therapeutic targetnoveloutcome forecastprognosticpromotersmall hairpin RNAtumortumorigenesisvector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Human T-cell Leukemia Virus type 1 (HTLV-I) is the etiological agent of adult T-cell leukemia (ATL), an aggressive and fatal disease characterized by a clonal expansion of virus-infected CD4+T cells. It is estimated that 20 to 30 million people worldwide are infected with HTLV-I. ATL has one of the poorest prognoses, with a median survival of 6-9 months in the acute phase and 10-12 months in the lymphoma phase. Overall, survival of ATLL patients treated with various chemotherapy or radiotherapy regimens is limited, as most patients relapse with aggressive tumors and succumb shortly thereafter. The molecular basis of HTLV-I oncogenesis is not well understood. The low incidence and long latency before the onset of the disease suggest that accumulation of genetic alterations of host infected cells is required for disease progression. We have found that microRNA miR-124a is specifically down-regulated through epigenetic silencing of its promoter in ATL cells. In this proposal, we will further characterize the role of miR-124a on the proliferation and survival of HTLV-I infected cells. We will then study the potential cooperation between miR-124a and other microRNA deregulated in HTLV-I transformed cells. Since miR-124a is down regulated in many human cancers, this proposal has the potential for broad implications.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.neo.2015.04.005
发表时间:
2015-05
期刊:
NEOPLASIA
影响因子:
4.8
作者:
[Moles, Ramona, Bellon, Marcia, Nicot, Christophe]
通讯作者:
Nicot, Christophe
Role of Tax and HBZ in HTLV-1C replication in vivo
-
批准号:10673788
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2022
-
负责人:CHRISTOPHE P NICOT
-
依托单位:
Role of Tax and HBZ in HTLV-1C replication in vivo
-
批准号:10526600
-
项目类别:
-
资助金额:$23.24万
-
财政年份:2022
-
负责人:CHRISTOPHE P NICOT
-
依托单位:
How HTLV-I Tax and HBZ control telomerase activity to induce adult T-cell leukemia
-
批准号:9513500
-
项目类别:
-
资助金额:$34.71万
-
财政年份:2016
-
负责人:CHRISTOPHE P NICOT
-
依托单位:
How HTLV-I Tax and HBZ control telomerase activity to induce adult T-cell leukemia
-
批准号:9304181
-
项目类别:
-
资助金额:$34.72万
-
财政年份:2016
-
负责人:CHRISTOPHE P NICOT
-
依托单位:
Role of HTLV-I Tax-induced NF-kB in activation of ICN1 and immortalization of vir
-
批准号:8435077
-
项目类别:
-
资助金额:$18.88万
-
财政年份:2013
-
负责人:CHRISTOPHE P NICOT
-
依托单位:
Role of HTLV-I Tax-induced NF-kB in activation of ICN1 and immortalization of vir
-
批准号:8606171
-
项目类别:
-
资助金额:$22.65万
-
财政年份:2013
-
负责人:CHRISTOPHE P NICOT
-
依托单位:
Role of miR-124a in HTLV-I oncogenesis
-
批准号:8189473
-
项目类别:
-
资助金额:$19.58万
-
财政年份:2011
-
负责人:CHRISTOPHE P NICOT
-
依托单位:
SIGNAL TRANSDUCTION CORE
-
批准号:8168399
-
项目类别:
-
资助金额:$7.63万
-
财政年份:2010
-
负责人:CHRISTOPHE P NICOT
-
依托单位:
SIGNAL TRANSDUCTION CORE
-
批准号:7959696
-
项目类别:
-
资助金额:$7.17万
-
财政年份:2009
-
负责人:CHRISTOPHE P NICOT
-
依托单位:
Uncoupling of Jak/STAT in HTLV-1 associated leukemia
-
批准号:7915825
-
项目类别:
-
资助金额:$20.64万
-
财政年份:2009
-
负责人:CHRISTOPHE P NICOT
-
依托单位:
SIGNAL TRANSDUCTION CORE
-
批准号:7720550
-
项目类别:
-
资助金额:$6.66万
-
财政年份:2008
-
负责人:CHRISTOPHE P NICOT
-
依托单位:
Uncoupling of Jak/STAT in HTLV-1 associated leukemia
-
批准号:7470729
-
项目类别:
-
资助金额:$22.34万
-
财政年份:2007
-
负责人:CHRISTOPHE P NICOT
-
依托单位:
Uncoupling of Jak/STAT in HTLV-1 associated leukemia
-
批准号:8067051
-
项目类别:
-
资助金额:$21.67万
-
财政年份:2007
-
负责人:CHRISTOPHE P NICOT
-
依托单位:
SIGNAL TRANSDUCTION CORE
-
批准号:7609900
-
项目类别:
-
资助金额:$7.12万
-
财政年份:2007
-
负责人:CHRISTOPHE P NICOT
-
依托单位:
Uncoupling of Jak/STAT in HTLV-1 associated leukemia
-
批准号:7259713
-
项目类别:
-
资助金额:$22.34万
-
财政年份:2007
-
负责人:CHRISTOPHE P NICOT
-
依托单位:
Uncoupling of Jak/STAT in HTLV-1 associated leukemia
-
批准号:7840480
-
项目类别:
-
资助金额:$22.34万
-
财政年份:2007
-
负责人:CHRISTOPHE P NICOT
-
依托单位:
Uncoupling of Jak/STAT in HTLV-1 associated leukemia
-
批准号:7623538
-
项目类别:
-
资助金额:$22.34万
-
财政年份:2007
-
负责人:CHRISTOPHE P NICOT
-
依托单位:
SIGNAL TRANSDUCTION CORE
-
批准号:7381295
-
项目类别:
-
资助金额:$1.63万
-
财政年份:2006
-
负责人:CHRISTOPHE P NICOT
-
依托单位:
BREAKING HTLV-I LATENCY: P30-RNA INTERACTIONS A NOVEL THERAPEUTIC TARGET
-
批准号:7170520
-
项目类别:
-
资助金额:$7.29万
-
财政年份:2005
-
负责人:CHRISTOPHE P NICOT
-
依托单位:
Regulation of HTLV-I replication by the viral p30
-
批准号:7387428
-
项目类别:
-
资助金额:$23.93万
-
财政年份:2005
-
负责人:CHRISTOPHE P NICOT
-
依托单位:
海外基金